focus -WSS

focus

author：knowledge 2025-09-02 22:09:13 - browse：96599

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Rise in cancer among younger people worries and puzzles doctors

WSS

Device maker Teleflex to acquire urology company for $600M

Awakening the world to the whoosh: A patient's crusade

Dems pitch expanding Medicare power to negotiate drug prices

Device maker Teleflex to acquire urology company for $600M

STAT Report: Patient voices and perspectives

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medicare details structure of new drug price negotiation program

EF3 tornado rips through North Carolina amid extreme weather nationwide

Heart attack and stroke risk calculators need revising

Device maker Teleflex to acquire urology company for $600M

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

7 more heat

The cancer drug shortage isn’t new — and neither are the solutions

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Bright Health sells Medicare Advantage business to Molina

Awakening the world to the whoosh: A patient's crusade

leisure time

Study identifies new proteins linked to dementia risk 25 years later

I learned firsthand about improving diversity in clinical trials

Device maker Teleflex to acquire urology company for $600M

7 more heat

Hospitals struggle to profit from CAR

Will the FTC rein in IQVIA's health data empire?

knowledge

Wikipedia

focus

entertainment